title: Effect of ingesting sour milk fermented using Lactobacillus helveticus bacteria producing tripeptides on blood pressure in subjects with mild hypertension.
abstract: Angiotensin-converting enzyme (ACE) is important in the regulation of blood pressure (BP). Two tripeptides that inhibit ACE, isoleucyl-prolyl-proline (Ile-Pro-Pro) and valyl-prolyl-proline (Val-Pro-Pro), have been isolated from certain sour milks. The aim of the study reported was to evaluate the effect on BP in subjects with mild hypertension of a new sour milk containing tripeptides. The initial number of subjects was 60 (36 men, 24 women). Among the criteria for inclusion in the study were systolic BP (SBP) between 140 and 180 mmHg and/or diastolic BP (DPB) between 90 and 110 mmHg, without antihypertensive drug therapy. There were two study periods with a washout period between. All subjects were given 1.5 dl per day of a placebo (regular sour milk) or of the active product, a milk that had been fermented with Lactobacillus helveticus bacteria and contained 2.4-2.7 mg of Ile-Pro-Pro and 2.4-2.7 mg of Val-Pro-Pro per 1.5 dl. In the first phase, SBP fell 16 mmHg from baseline in the active group, 2 mmHg more than in the placebo group (P=0.0668) and no difference in DBP (P=0.92). There was a statistically significant downward trend both in SBP and DBP (P=0.0001). During the second phase, SBP fell 11 mmHg in the active group (P=0.008). The reduction in SBP was significantly larger in active than placebo group (P=0.012). In the crossover analysis combining both phases, SBP fell on average 2.6+/-15.9 mmHg more on the active product compared with the placebo product, but this difference was not statistically significant (P=0.3111). The difference in DBP, 1.0+/-8.3 mmHg between the two test products was not significant either (P=0.4431). In conclusion, the ingestion of sour milk fermented by L. helveticus bacteria and that containing ACE inhibitory tripeptides seems to lower BP modestly.
authors.affiliation: Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland. jaakko.tuomilehto@ktl.fi
authors.forename: J
authors.initials: J
authors.lastname: Tuomilehto
authors.forename: J
authors.initials: J
authors.lastname: Lindström
authors.forename: J
authors.initials: J
authors.lastname: Hyyrynen
authors.forename: R
authors.initials: R
authors.lastname: Korpela
authors.forename: M-L
authors.initials: ML
authors.lastname: Karhunen
authors.forename: L
authors.initials: L
authors.lastname: Mikkola
authors.forename: T
authors.initials: T
authors.lastname: Jauhiainen
authors.forename: L
authors.initials: L
authors.lastname: Seppo
authors.forename: A
authors.initials: A
authors.lastname: Nissinen
mesh_terms: D000704:Analysis of Variance; D018592:Cross-Over Studies; D005260:Female; D005285:Fermentation; D005387:Finland; D006801:Humans; D006973:Hypertension / Q000178:diet therapy*; D007778:Lactobacillus; D008297:Male; D008875:Middle Aged; D008894:Milk Proteins / Q000008:administration & dosage*; D009842:Oligopeptides / Q000008:administration & dosage*
chemical_list: D008894:Milk Proteins; D009842:Oligopeptides; C489032:isoleucyl-prolyl-proline; C489031:valyl-prolyl-proline